GI Alliance of Illinois Moves to Upgraded Facility
17 avr. 2024 08h35 HE
|
GI Alliance
EVANSTON, IL, April 17, 2024 (GLOBE NEWSWIRE) -- GI Alliance of Illinois, a local gastroenterology practice that offers cutting-edge treatment in Evanston, IL, has moved to a new gastro clinic,...
2nd Annual Butts & Guts 5K Presented by Giant Leap Foundation
15 avr. 2024 07h35 HE
|
GI Alliance
New Orleans, LA, April 15, 2024 (GLOBE NEWSWIRE) -- Giant Leap Foundation - a non-profit organization dedicated to promoting health and wellness initiatives in communities across the nation - is...
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs
10 avr. 2024 11h48 HE
|
University, Cancer and Blood Center
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs.
Arizona Digestive Health Expands Into Tucson
10 avr. 2024 10h35 HE
|
GI Alliance
TUCSON, Arizona, April 10, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health, the premier gastroenterology practice in Arizona, has opened a new gastro clinic and an endoscopy center, both located...
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
05 avr. 2024 09h17 HE
|
Spherix Global Insights
EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
22 mars 2024 10h14 HE
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h05 HE
|
Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
20 mars 2024 06h21 HE
|
CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
Short Bowel Syndrome (SBS) Market Projected to Surge to $5.7 Billion Globally by 2030, with High CAGR in GLP-2 and Growth Hormone Segments
06 mars 2024 10h24 HE
|
Research and Markets
Dublin, March 06, 2024 (GLOBE NEWSWIRE) -- The "Short Bowel Syndrome (SBS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global Short Bowel...
US Digestive Health Celebrates Grand Opening of Lansdale-Colmar Office
15 févr. 2024 10h00 HE
|
US Digestive Health
EXTON, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the nation's largest gastroenterology (GI) practices, celebrated the opening of its new Lansdale-Colmar office on...